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Dkk-3 is a newly characterised mortalisation-related gene and an antagonist of the Wnt oncogenic signalling pathway whose
expression is decreased in a variety of cancer cell lines, suggesting that the Dkk-3 gene, located at chromosome 11p15.1, functions as
a tumour suppressor gene. Although 11p15 is a ‘hot spot’ for methylation in acute lymphoblastic leukaemia (ALL), the role of Dkk-3
abnormalities has never been evaluated in this disease. We analysed CpG island methylation of the Dkk-3 promoter in six ALL cell
lines and 183 ALL patients. We observed Dkk-3 hypermethylation in all cell lines and in cells from 33% (60/183) of ALL patients.
Moreover, Dkk-3 methylation was associated with decreased Dkk-3 mRNA expression and this expression was restored after
exposure to the demethylating agent 5-AzaC. Clinical features did not differ between hypermethylated and unmethylated patients.
Estimated disease-free survival (DFS) and overall survival at 10 and 11 years, respectively, were 49.8 and 45.6% for normal patients
and 10.5 and 15.1% for hypermethylated patients (P¼0.001 and 0.09). Multivariate analysis demonstrated that Dkk-3 methylation
was an independent prognostic factor predicting DFS (P¼0.0009). Our data suggest that Dkk-3 methylation occurs at an early stage
in ALL pathogenesis and probably influences the clinical behaviour of the disease.
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DNA methylation is an essential mechanism for the regulation of
gene expression in mammalian cells (Bird, 2002). Methylation
occurs at cytosine residues within CpG dinucleotides and many
genes are enriched with these dinucleotides in their promoters.
These regions are known as CpG islands and are generally
nonmethylated, a condition that allows genes to be transcription-
ally competent. Methylation of CpG islands within gene promoters
leads to transcriptional silencing through recruitment of methyl-
CpG binding protein and histone deacetylases (Jones and Baylin,
2002). Hence, identification of the methylation patterns of CpG
islands in mammalian cells is important for understanding normal
and pathological gene expression. Several reports have shown that
abnormal hypermethylation of CpG islands may contribute
significantly to the pathogenesis of human leukaemias. Hyper-
methylation of promoters associated with genes involved in the
control of the principal late-G1 cell-cycle checkpoint, the apoptotic
programme and the cell–cell adhesion is detected with increased
frequency in acute lymphoblastic leukaemia (ALL) (Roman-Gomez
et al, 2003). This mechanism provides an alternative route to gene
mutation of cancer-related genes. Although genomewide methyla-
tion changes in CpG islands are early and frequent events in ALL,
it is also evident that some of these changes occur preferentially in
specific chromosome regions. In this context, 11p15 region seems
to represent a ‘hot spot’ for methylation in ALL. In fact, epigenetic
inactivation of Calcitonin (11p15.1–15.2), p57 (11p15.5) and Myf-3
(11p15.4) genes are frequently observed in both childhood and
adult ALL (Roman-Gomez et al, 2001; Garcia-Manero et al, 2002;
Li et al, 2002). Interestingly, Calcitonin gene is methylated in a
large proportion of ALL patients with dismal prognosis. However,
this gene is generally considered not to be causally related to the
malignant process suggesting that its methylation is a surrogate for
the methylation of another potential tumour suppressor gene
located in its vicinity.
The human Dickkopfs-3 (Dkk-3) gene, located on chromosome
11p15.1 is a recently found mortalisation-related gene expression
of which is largely attenuated in many immortalised and tumour-
derived cell lines (Tsuji et al, 2000). Furthermore, by transfection
experiments, it has been determined that Dkk-3 possesses an
antiproliferative activity against tumour cells, suggesting that Dkk-
3 may function as a tumour suppressor (Tsuji et al, 2001).
Recent studies have shown that some Dkks play a role in a wide
range of normal and pathological developmental processes,
including cancer, and that their effects seem to be mediated by
their ability to antagonise Wnt signalling (Taipale and Beachy,
2001). Wnt signalling pathway has profound effects in normal
haematopoiesis inducing bone marrow cells to develop into a
variety of different lymphoid cell types and also augmenting
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human blood stem cell in vivo (Brandon et al, 2000). In addition,
expression of Wnt-16 following a chromosomal translocation has
been reported in preB-cell ALL (McWhirter et al, 1999) and Wnt5a
hemizygous mice develop myeloid leukaemias and B-cell lympho-
mas that are clonal in origin suggesting a role for Wnts in
leukaemogenesis. However, little is known about the potential role
of Wnt antagonists in lymphoid neoplasia.
In this paper, we demonstrate that the putative tumour
suppressor Dkk-3 gene is silenced by methylation in ALL and that
this epigenetic event confers poor prognosis in this group of
patients.
MATERIALS AND METHODS
Cell lines and samples
Four human precursor-B ALL (BV173, TOM-1, MY and NALM-20)
and two T-cell leukaemia (MOLT-3 and MOLT-4) cell lines were
obtained from the American Type Culture Collection (Manassas,
VA, USA). The cells were cultured in the appropriate medium until
harvested for extraction of DNA and RNA using standard
procedures. Bone marrow samples obtained by aspiration were
collected after an acquisition of informed consent from 183
consecutive patients (106 male; 77 female) who were diagnosed
with de novo ALL between January 1989 and December 2002.
Mononuclear cells were isolated from samples at diagnosis by a
Ficoll–Paque gradient as per the manufacturer’s instructions
(Amersham Pharmacia Biotech AB, Uppsala, Sweden). In all the
cases, the diagnostic bone marrow sample contained blast cells in
the ratio of at least 70%.
The median age at diagnosis in the study population as a whole
was 14.5 years (range, 0.5–82 years). Of these patients, 92 were
children (median age, 5 years; range, 0.5–14) and 91 presented
adult ALL (median age, 35 years; range, 15–82). Diagnosis was
established according to standard morphologic, cytochemical and
cytogenetic criteria. Patients were studied at the time of initial
diagnosis; were risk-stratified according to the therapeutic
protocol used, which was always based on recognised prognostic
features (including cytogenetics); and were entered in ALL
protocols of the ‘Programa para el estudio y tratamiento de las
hemopatias malignas’ (PETHEMA) Spanish study group. For
statistical analyses, children were also grouped according to the
National Cancer Institute (NCI) risk-classification criteria (Smith
et al, 1996). The specific PETHEMA ALL treatment protocols in
which these patients entered included ALL-89 (between 1989 and
1994; n¼53) and ALL-93 (between 1994 and 2002; n¼130). The
design and results of these studies have been previously reported
(Ortega, 1998; Ribera et al, 1998; Ortega et al, 2001; Ribera et al,
2002). In all, 64 patients relapsed. Overall, 29 patients received
stem cell transplantation (10 autologous, 19 allogeneic) in the first
(n¼12) or second complete remission (CR) (n¼17). There are 91
patients currently alive. Clinical characteristics of the patients are
listed in Table 1. Some of these patients (n¼105) were typed
previously for methylation of the Calcitonin gene (Roman-Gomez
et al, 2001).
Quantitative real-time PCR (qrt-PCR) for Dkk-3 expression
Total RNA was extracted from mononuclear marrow cells with
Ultraspec (Biotecx, Houston, TX, USA) following the manufac-
turer’s instructions. Reverse transcription was performed on 1mg
total RNA, after heating at 701C for 5min, with random hexamers
as reaction primer. The reaction was carried out at 421C for 45min
in the presence of 12U Avian Myeloblastosis virus reverse
transcriptase (Boehringer-Mannhein, Germany). qrt-PCR was
performed in a rapid fluorescent thermal cycler with three-colour
fluorescence monitoring capability (LightCycler, Roche), using 1ml
of cDNA in 20ml reaction volume with 0.4mmoll
 1 each primer,
and 2mlo f1 0  LightCycler FastStar DNA Master SYBR Green I
(Roche Molecular Biochemicals). The final Mg
2þ concentration in
the reaction mixture was adjusted to 3.5mmoll
 1. Primer set was
specific for the Dkk-3 gene ( Homo sapiens Dkk-3 mRNA,
GeneBank: AB033421; sense, 50-CTGTGTGTCTGGGGTCACTG-30;
antisense, 50-GCTCTAGCTCCCAGGTGATG-30). The following
programme conditions were applied for qrt-PCR running:
denaturation programme, consisting of one cycle at 951C for
8min; amplification programme, consisting of 45 cycles at 951C for
5s,601C for 10s and 721C for 15s; melting programme, one cycle
at 951C for 0s, 401C for 60s and 901C for 0s; and cooling
programme, one cycle at 401C for 60s. The temperature transition
rate was 201Cs
 1, except in the melting programme, which was
0.41Cs
 1 between 40 and 901C.
Amplification of Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene transcript was performed to assess RNA integrity
and as reference gene (forward, 50-TGAAGGTCGGAGTCAACG-
GATTTGGT-30; reverse, 50-CATGTGGGCCATGAGGTCCACCAC-
30). It was amplified in the same run and following the
same procedure described above for Dkk-3. In order to
reduce the variation between different assays and samples, a
procedure based on the relative quantification of target genes vs
their controls in relation to the reference gene was used.
Calculations were automatically performed by LightCycler soft-
ware (RealQuant, version 1.0, Roche). The normalised ratio was
obtained from the next equation and expressed as percentage of
the control:
NormalisedratioðNDDK 3Þ¼
ðEtargetÞ
DCptargetðcontrol sampleÞ  ð ErefÞ
DCprefðcontrol sampleÞ
Efficiencies (E) of each gene were calculated from the slopes of
crossover points (Cp) vs cDNA concentration plot, according to
the formula E¼10
( 1/slope). DCp corresponded to the difference
between control Cp and sample Cp, either for the target or for the
reference genes. The selected control was the bone marrow
specimen from a healthy donor. It was considered as 100%
expression. Occasionally, equal amounts of PCR products were
separated on a 2% agarose gel, stained with ethidium bromide, and
visualised under UV light.
Methylation-specific PCR (MSP) of Dkk-3 promoter
Analysis of the Dkk-3 gene (GeneBank: AB045205, Homo sapiens
Dkk-3 gene) has revealed that Dkk-3 promoter was CpG-rich,
showing 460% CþG content and an observed-overexpected CpG
frequency of 40.6, satisfying the criteria for a CpG island.
Aberrant promoter methylation of Dkk-3 gene was determined by
method of MSP as previously reported (Herman et al, 1996). MSP
distinguishes unmethylated alleles of a given gene based on DNA
sequence alterations after bisulphite treatment of DNA, which
converts unmethylated but not methylated cytosines to uracils.
Subsequent PCR using primers specific to sequences correspond-
ing to either methylated or unmethylated DNA sequences was then
performed. Primer sequences of Dkk-3 for the unmethylated
reaction were forward (50-TTTTGGTTTTTTTTTGTTTTTGGG-30)
and reverse (50-CCAAACCACTACATCTCCACT-30), which amplify
a 179-bp product. Primer sequences for the methylated reaction
were forward (50-CGGTTTTTTTTCGTTTTCGGG-30) and reverse
(50-CAAACCGCTACATCTCCGCT-30), which amplify a 175-bp
product. Briefly, 1mg of genomic DNA were denatured by
treatment with NaOH and modified by sodium bisulphite. DNA
samples were purified using Wizard DNA purification resin
(Promega Corp., Madison, WI, USA), treated with NaOH,
precipitated with ethanol, and resuspended in 20ml of water.
A volume of 2ml of modified DNAs were PCR amplified in a
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ytotal volume of 50ml. ‘Hot start’ PCR was performed for
35 cycles consisting of denaturation at 951C for 1min,
annealing at 601C for 1min, and extension at 721C for 1min,
followed by a final 7-min extension for all primer sets. DNA
from mononuclear marrow cells (n¼20) from healthy donors
were used as negative controls for methylation-specific assays.
Human male genomic DNA universally methylated for all genes
(Intergen Company, Purchase, NY, USA) was used as a positive
control for methylated alleles. Water blanks were included with
each assay. PCR products were visualised on 2% agarose gels
stained with ethidium bromide. Results were confirmed by
repeating bisulphite treatment and MSP assays for all samples.
The sensitivity of this MSP was established by using totally
methylated, positive control DNA serially diluted by normal
lymphocyte DNA. MSPs with 1:10, 1:100, and 1:1000 diluted
positive control DNA produced detectable methylated bands (data
not shown).
Western blot analysis of Dkk-3 protein expression
For immunoblotting, proteins were extracted from B-lineage ALL-
derived MY cell line and MY cell line treated with 1, 2, 4 or 6mM of
5-Aza-20-deoxycytidine during 4 days. Cells from MY and treated
MY cell lines were washed in PBS and lysed in Triton lysis buffer
(1% Triton X-100, 50mM Tris-HCl pH 8, 150mM NaCl, 1mM PMSF
and 1% aprotinin). The supernatant was collected by centrifuga-
tion at 15000g, 20min, 41C, and the protein concentration was
determined using BCA protein assay kit (Pierce, Rockford, IL,
USA). Cell lysates (containing 50mg of proteins) were size-
fractionated by 10% SDS–PAGE and electrotransferred to
nitrocellulose membranes. The membranes were blocked with I-
Blockt (Tropix, Bedford, MA, USA) and incubated for 2h with
goat polyclonal antibody against Dkk-3 (Santacruz Biotechnology,
Santa Cruz, CA, USA) diluted 1:750 and then with donkey anti-
goat antibody conjugated to alkaline phosphatase (Promega,
Madison, WI, USA) diluted 1:15000 for 45min. As loading
control, the membranes were incubated for 1h with mouse
monoclonal antibody against b-tubulin diluted 1:1000 and then
with goat anti-mouse antibody conjugated to alkaline phosphatase
(Sigma, Steinheim, Germany) diluted 1:10000 for 45min. Finally,
bound antibodies were detected by a chemiluminescence system
(Tropix, Bedford, MA, USA). For detection of secreted proteins,
20ml of filtered, dialysed, conditioned media, collected after 48h of
incubation with MY and treated MY cell lines, was analysed by
Western blotting.
Statistical analysis
P-values for comparisons of continuous variables between groups
of patients were two-tailed and based on the Wilcoxon rank-sum
test. P-values for dichotomous variables were based on the Fisher
exact test. The remaining P-values were based on the Pearson w
2-
test. Overall survival (OS) was measured from the day of diagnosis
until death from any cause and was only censored for patients
known to be alive at last contact. Disease-free survival (DFS) was
measured from the day that complete response (CR) was
established until either relapse or death without relapse, and it
was only censored for patients who were alive without evidence of
relapse at the last follow-up. Distributions of OS and DFS curves
were estimated by the method of Kaplan and Meier with 95%
confidence intervals calculated using Greenwood’s formula.
Comparisons of OS or DFS between groups were based on the
log-rank test. Comparisons adjusted for significant prognostic
factors were based on Cox regression models and hazard
regression models. All relapse and survival data were updated on
31 December 2003 and all follow-up data were censored at this
point.
RESULTS
Dkk-3 expression is downregulated in ALL samples and
T/B-precursor ALL cell lines
To determine the cutoff point for altered Dkk-3 expression in ALL
samples, the NDDK-3 value for Dkk-3 was determined in 20 bone
marrow samples from healthy donors. NDDK-3 values fell between
107 and 86% (mean: 96.575.6%). A NDDK-3 value below 68.5%
(determined as the mean75s.d.) was chosen to define under-
expression of Dkk-3 in ALL RNA samples. No Dkk-3 expression
was observed in T- or B-precursor ALL cell lines (Figure 1B). In
addition, we found a strong reduction of Dkk-3 mRNA in 41% of
diagnostic ALL samples (NDDK-3: mean, 23%; range, 47–0%). No
overexpression of Dkk-3 (NDDK-3 above 107%) was observed in
ALL primary tumours.
Methylation of Dkk-3 promoter is associated with reduced
mRNA expression
To investigate a mechanism for the reduced expression of the Dkk-
3 gene, we analysed Dkk-3 promoter, which is known to be
methylated in cancer cell lines lacking Dkk-3 expression (Kobaya-
shi et al, 2002). Promoter of the Dkk-3 gene has a typical CpG
island showing 460% CþG content and an observed-over-
expected CpG frequency of 40.6. By MSP, CpG island of the Dkk-3
promoter was revealed to be highly methylated in all ALL cell lines
(Figure 1A) and in 60 of 183 (33%) samples from patients with ALL
(Figure 1C), which was clearly in contrast to no Dkk-3 methylation
in normal cells.
All 60 methylated ALLs (100%) showed decreased Dkk-3
expression; in contrast, decreased Dkk-3 expression was detected
in only 10 of 123 ALLs with unmethylated pattern (8%). This result
indicated that CpG methylation within Dkk-3 promoter strongly
correlated with decreased constitutive expression of Dkk-3 in ALL
cells (Po0.0001).
Exposure to different concentration of the demethylating agent
5-Aza-20-deoxycytidine restored, in both cell lysate and culture
supernatant, the expression of Dkk-3 protein in the MY ALL cell
line indicating that hypermethylation is a major mechanism by
which Dkk-3 expression is silenced in ALL cells (Figure 1D).
Dkk-3 methylation, clinical presentation and outcome: Dkk-3
methylation was detected at diagnosis in 33% (60 out of 183) of
patients with adult or childhood ALL of all the FAB subtypes. As
shown in Table 1, aberrant Dkk-3 methylation was similarly
observed in adults (30 out of 91, 33%) and children (30 out of 92,
32%). Clinical and laboratory features did not differ significantly
between methylated and normal patients. Poor-risk cytogenetics or
molecular events, risk groups according to both NCI or PETHEMA
classifications, good risk features (hyperdiploidy and TEL-AML1
fusion), type of PETHEMA protocol administered and number of
patients who received stem cell transplantation were similarly
distributed between the two groups defined by Dkk-3 methylation.
Separate analysis of adult and childhood ALL patients gave the
same results as the global series. The presence of methylation in
the Calcitonin gene was determined previously for 105 of these
cases (Roman-Gomez et al, 2001). There was a significant
concordance between Dkk-3 methylation and the presence of
Calcitonin methylation; methylation was present in 30 out of 42
(71.4%) Calcitonin-methylated tumours vs 13 out of 63 (20.6%)
Calcitonin nonmethylated tumours (P¼0.0001).
Table 1 details the relapse history, CR rates and mortality for
patients who exhibited Dkk-3 methylation and the equivalent data
for patients with normal Dkk-3 gene. CR rates of patients with
normal and methylated Dkk-3 gene were 90 and 92%, respectively,
accounting for 91% of the overall CR rate. This suggests that
methylation of the Dkk-3 gene did not correlate with response to
remission induction therapy. However, methylated patients had a
Dkk-3 methylation in ALL
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patients. Similar results were obtained in the separate analyses of
children (relapse rate: 46 vs 25%, P¼0.04) and adults (relapse rate:
71 vs 45%, P¼0.03).
We analysed the DFS among patients who achieved CR
according to Dkk-3 methylation. Estimated DFS rates at 10 years
were 49.8 and 10.5% for normal and methylated patients,
respectively (P¼0.001) (Figure 2A). Among unmethylated chil-
dren, the 10 years DFS was 60.6% contrasting with 17.6% for
hypermethylated children (P¼0.03, Figure 2B). Among adult ALL
patients, the 9-years DFS was 6.8% for methylated cases and 37.7%
for normal cases (P¼0.01, Figure 2C). The actuarial OS calculated
for all leukaemic patients was 45.6 and 15.1% at 11 years for cases
with normal and hypermethylated Dkk-3 gene, respectively
(P¼0.09).
A multivariate analysis of potential prognostic factors (including
the type of PETHEMA protocol applied) demonstrated that
methylation of the Dkk-3 gene was an independent prognostic
factor in predicting DFS in the global series and also in both,
childhood and adult ALL (Table 2).
DISCUSSION
Mammalian cells have a finite replicative potential in vitro and in
vivo referred to as the Hayflick limit (Hayflick, 1997). Upon
reaching this limit, cells cease to divide and undergo genetic,
biochemical and morphological changes indicative of ageing, a
state referred to as cellular senescence. As these cells do not
proliferate, it has been suggested that cellular senescence is a major
barrier against cancerous transformation. The ability to overcome
senescence and obtain a limitless replicative potential (termed
immortalisation), is one of the prerequisites for tumour transfor-
mation (Hanahan and Weinberg, 2000). If downregulation of a
gene can lead to the immortalisation of cells, the gene may be a
candidate of tumour suppressor gene. Recently, a mortalisation-
related gene was isolated by the representational difference
analysis system with an immortalised cell line and the normal
counterpart (Tsuji et al, 2000). A search of this gene revealed that
it was identical with the human Dkk-3 gene, an antagonist of the
Wnt oncogenic pathway. More recently, it has been reported that
Dkk-3 expression was reduced by methylation in several cancer cell
lines and primary lung cancers (Kobayashi et al, 2002).
Dkk-3 gene could be a good candidate for epigenetic inactivation
in ALL. It is located near the Calcitonin gene, a gene known to be
methylated in ALL patients with unfavourable prognosis (Roman-
Gomez et al, 2001). However, this gene is generally considered not
to be causally related to the malignant process, suggesting that
methylation status of the Calcitonin gene region in ALL
lymphoblasts may well correspond to that of its neighbouring
Dkk-3 gene. In this study, we have identified the Dkk-3 gene as a
target gene for methylation and silencing in ALL. Dkk-3 locus
methylation was detected in six ALL-derived cell lines and in 33%
of tumours at diagnosis, indicating that inactivation of the Dkk-3
gene is a frequent and early event in the process of tumorigenesis
in this disease. Methylation of the Dkk-3 promoter region was
associated with loss of Dkk-3 gene expression in neoplastic
cells and this expression was restored after exposure to the
A
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Figure 1 Methylation status and expression levels of Dkk-3 in ALL cell lines and patients. (A) MSP analysis of CpG island within Dkk-3 promoter in five ALL
cell lines. Pos-C indicates methylated control; Neg-C indicates unmethylated control (marrow mononuclear cells from a healthy donor); UM¼unmethylated
alleles; M¼methylated alleles. Promoter hypermethylation is observed in all cell lines. (B) RT–PCR analysis with the Dkk-3 and GAPDH (as control for
mRNA integrity) primers. Neg-C indicates unmethylated control. Lack of Dkk-3 expression in observed in all cell lines. (C) MSP analysis of CpG island within
Dkk-3 promoter in 12 ALL patients. (D) Analysis of Dkk-3 protein expression by Western blot. The levels of beta-tubulin were also analysed as loading
control. 1: ALL-derived MY cell line; 2–4: MY cell line treated with 2, 4 or 6mM of 5-Aza-20-deoxycytidine. The demethylating agent restores Dkk-3
expression.
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major mechanism by which Dkk-3 expression is silenced in ALL
cells. Moreover, a significant concordance between Dkk-3 methy-
lation and Calcitonin methylation was observed, suggesting that
Calcitonin methylation is a surrogate for the methylation of the
Dkk-3 gene.
What is the functional significance underlying the methylation-
mediated transcriptional loss of Dkk-3 in ALL? During replicative
senescence altered expression of genes that are involved in cell
cycle control and oncogenesis is well documented. A senescence-
like arrest can be induced by ectopic expression of p15
INK4b,
p16
INK4a, p21
CIP or by DNA-damaging agents that activate p53
(Serrano et al, 1997; Stein et al, 1999). These findings are
consistent with a model in which the concurrent induction of a
mitogenic stimulus with a forced G1 arrest may be sufficient to
induce a senescent phenotype. Senescence, much like apoptosis,
represents a major barrier to tumorigenesis and it can be achieved
by shortened telomeres or conflicting growth signals that forces
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Figure 2 Kaplan–Meier survivor function for ALL patients. DFS curves
for ALL patients enrolled in this study according to methylation status of
the Dkk-3 gene. Solid lines, unmethylated patients; dashed lines, methylated
patients.
Table 1 Clinical characteristics and outcome of 183 ALL patients
according to Dkk-3 gene methylation status
Feature
Nonmethylated
(n¼123), %
Methylated
(n¼60), % P
Age NS
Younger than 15 years 48 52
Older than 15 years 52 48
Sex
M/F 64/36 72/28 NS
WBC NS
Below 50 10
9l
 1 78 70
Above 50 10
9l
 1 22 30
FAB classification NS
L1 38 25
L2 50 64
L3 12 11
Blast lineage NS
B8 8 6 4
T1 2 3 6
NCI risk groups NS
Standard 80 65
Poor 20 35
Pethema risk groups NS
Standard 40 34
Poor 60 66
Treatment NS
Pethema 89 25 27
Pethema 93 75 73
BMT 19 10 NS
Best response NS
CR 90 92
Cytogenetic/molecular
Abnormalities NS
BCR-ABL 17 14
t(1;19) 4 2
11q23 3 3
c-Myc 6 8
7q35–14q11 6 8
Hyperdiploidy 9 5
TEL-AML1 5 3
Normal 46 52
Others 3 3
NT 1 2
Relapse 34 57 0.009
Death 41 48 NS
Data are expressed as percentages; WBC¼white bood count; FAB¼French–
American–British; NCI¼National Cancer Institute; PETHEMA¼Programa para el
estudio y tratamiento de las hemopatias malignas; BMT¼bone marrow transplanta-
tion; CR¼complete remission.
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The genetic changes associated with immortalisation, namely loss
of p16, p15, p21 and p53, are among the most common known
cancer-related changes, and these genes are frequently down-
regulated by methylation in ALL (Garcia-Manero et al, 2002;
Roman-Gomez et al, 2002; Agirre et al, 2003). Dkk-3 could
function in a similar way, confirming that epigenetic inactivation
of genes involved in senescence regulation plays a major role in the
pathogenesis of leukaemia. In addition, Dkk-3 could contribute to
leukaemogenesis by means of its ability to antagonise Wnt
proteins. Wnt pathway plays a crucial role in haematopoietic
differentiation (Brandon et al, 2000); and activation of a
‘canonical’ Wnt pathway is associated with several types of human
cancers, including B-cell malignancies (Qiang et al, 2003). The
‘transforming activity’ of Wnt is ascribed to the beta-catenin/
signalling pathway, which appears to be specifically activated by
Wnt7A protein (Sheldahl et al, 1999). Interestingly, Dkk-3
negatively modulates Wnt7A signalling (Caricasole et al, 2003).
Therefore, it can be speculated that lack of Dkk-3 expression
favours the activation of the most powerful Wnt protein related to
the development of cancer.
These findings, together with the prognostic impact of Dkk-3
inactivation in ALL, the general expression of Dkk-3 in normal
blood cells, the emerging role of the Dkk-3 gene in human cancer
and the observation that transfection of human osteosarcoma
Saos-2 cells with Dkk-3 entails a decrease in the proliferative
activity are supportive of Dkk-3 inactivation contributing directly
to the clinical behaviour of ALL, at least in a subgroup of patients.
In conclusion, our results strongly indicate that the silencing of
Dkk-3 expression by aberrant promoter methylation occurs at an
early stage of ALL pathogenesis and plays a role in the outcome of
the disease.
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